After kicking off March with the announcement of US Food and Drug Administration approval for two denosumab biosimilars, Sandoz has closed out April by revealing that it has secured a launch date of 31 May 2025 for the products through a litigation settlement with originator Amgen.
Sandoz Settlement Sets Date For US Denosumab Entry
Deal With Amgen Ends Litigation, Allowing Prolia/Xgeva Biosimilars To Launch Next Year
Sandoz has secured a launch date for its newly-approved US denosumab biosimilars, settling patent litigation with Prolia/Xgeva originator Amgen.
